Kai-Keen Shiu

Kai-Keen Shiu

KEYNOTE-177: translating results for patients and clinicians 3:36
KEYNOTE-177: translating results for patients and clinicians
Kai-Keen Shiu • 17 Jan 2021
KEYNOTE-177 discussion: chemo-immunotherapy, pseudoprogression & biomarkers 6:57
KEYNOTE-177 discussion: chemo-immunotherapy, pseudoprogression & biomarkers
Kai-Keen Shiu • 17 Jan 2021
KEYNOTE-177: final PFS analysis of pembrolizumab in patients with MSI-H/dMMR mCRC 2:56
KEYNOTE-177: final PFS analysis of pembrolizumab in patients with MSI-H/dMMR mCRC
Kai-Keen Shiu • 17 Jan 2021
Current challenges and key developments in CRC 4:00
Current challenges and key developments in CRC
Kai-Keen Shiu • 27 Sep 2019
CUPISCO & GEFCAPI04: molecularly-guided therapy in cancer of unknown primary 2:14
CUPISCO & GEFCAPI04: molecularly-guided therapy in cancer of unknown primary
Kai-Keen Shiu • 27 Sep 2019
ctDNA measurement via liquid biopsies in cancer of unknown primary 1:44
ctDNA measurement via liquid biopsies in cancer of unknown primary
Kai-Keen Shiu
Liquid biopsy assays: how best to use them 1:58
Liquid biopsy assays: how best to use them
Kai-Keen Shiu
Using AI to design clinical trials 1:26
Using AI to design clinical trials
Kai-Keen Shiu
Future prospects for treating rectal cancer 1:40
Future prospects for treating rectal cancer
Kai-Keen Shiu • 14 Jun 2018
The content of VJOncology is intended for healthcare professionals